Our Solutions

Across the full commercialization journey
Enter and win in Korea — without building a subsidiary.

We take rare disease and specialty care therapies from market assessment to full commercial operations — as your advisor, or as your MA holder on the ground.

Market Entry & Feasibility

• Market opportunity & feasibility analysis in rare disease & specialty care

• Pricing, reimbursement & market-access strategy — RSA, expenditure cap, outcome-based assessment

• Regulatory landscape & approval pathway assessment (MFDS, HIRA)

Virtual Subsidiary

• MA holdership & full regulatory ownership for foreign companies

• Distribution, supply & commercial operations in Korea

• Sales execution — field teams (MSL, MA, Sales & KAM)

Strategy & Capability Building

• Deep-dive training in rare disease & specialty markets, market access, pricing & reimbursement

• Organizational & team structuring — new business units and field force (MSL, MA, Sales)

• Commercial strategy & brand positioning; performance & productivity systems

Commercial Operations & Partnerships

• Co-promotion & CSO team deployment for hospitals and key accounts

• Key account management (KAM) — strengthening HCP & hospital access

• In-field support & performance tracking; market intelligence reports

ZBRA Expert Network (ZEN)

We provide a flexible, cost-efficient solution by leveraging a network of seasoned experts in the pharmaceutical and rare disease sectors. Our project-based approach ensures precision, efficiency, and impact.

Expert Outsourcing Pool: Access top-tier professionals in regulatory affairs, market access, legal, sales, and marketing.
Project-Based Expertise: Tailored teams assembled for each project, ensuring optimal strategy execution and measurable results.
Flexibility & Cost-Efficiency: Gain deep industry expertise without the overhead of a full-time team.